BPC-157 + TB-500 Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: No combination-specific human trials — see individual BPC-157 and TB-500 entries for their respective (also limited) evidence bases.

Animal evidence: No combination-specific animal trials either; each component has separate rodent literature.

Introduction & Mechanism of Action

Combination repair peptide blend studied for tissue-response, vascular-signaling and cell-migration research.

Pairs BPC-157's gut/tendon-repair signaling with TB-500's cell-migration and angiogenesis signaling — a popular research combination on the premise that the two mechanisms are complementary rather than redundant.

Receptors/targets: See individual BPC-157 and TB-500 entries

Areas of Research Interest

• Combined tissue-repair research
• Recovery and mobility studies

Benefits Reported in Research

• Combined tissue-repair research
• Recovery and mobility studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 250–500 mcg per component

Reported frequency: 1–2× daily, subcutaneous

Reported cycle duration: 4–8 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on BPC-157 + TB-500 reports administration at 250–500 mcg per component via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 20 mg vial with 2 mL bacteriostatic water, yielding a concentration of 10.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Injection-site irritation — see individual component entries

Contraindications

• Pregnancy
• Active malignancy (theoretical concern given angiogenic mechanisms)

Drug interactions

• Not characterized for the combination

Safety

• Combines the individually sparse safety profiles of both components
• No combination-specific human safety data

Combination-specific trials are essentially absent; see individual BPC-157 and TB-500 entries for their respective evidence bases.

Expected Results & Comparison

This is a combination of two peptides that each have their own (limited) individual evidence base — combination-specific trials are essentially absent, so it should be evaluated as "two experimental compounds used together," not as a separately validated product.

References

Continue